Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide.
The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.
Pandha
H S
HS
Department of Clinical Oncology, Hammersmith Hospital, London, UK.
Harrington
K
K
Saini
S
S
Lynn
J
J
Peters
M
M
Waxman
J
J
D000306:Adrenal Cortex Neoplasms / Q000150:complications*; D003480:Cushing Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000652:urine; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010166:Palliative Care; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
D013739:Testosterone; D015282:Octreotide; D006854:Hydrocortisone